Biologic determinants of uveal melanoma metastatic phenotype: Role of intermediate filaments as predictive markers

Laboratory Investigation

Volumn 78, Issue 2, 1998, Pages 153-163

  Hendrix, Mary J C ^a   Seftor, Elisabeth A ^a   Seftor, Richard E B ^a   Gardner, Lynn M ^a   Boldt, H Culver ^a   Meyer, Margaret ^a   Pe'er, Jacob ^b   Folberg, Robert ^a  

^a UNIVERSITY OF IOWA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

KERATIN; VIMENTIN;

ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; INTERMEDIATE FILAMENT; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEA MELANOMA;

ANTISENSE ELEMENTS (GENETICS); CHOROID NEOPLASMS; CILIARY BODY; FORECASTING; HUMANS; INTERMEDIATE FILAMENT PROTEINS; KERATINS; LIVER NEOPLASMS; MELANOMA; NEOPLASM INVASIVENESS; PHENOTYPE; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 0031936155     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Albert DM, Niffenegger AS, and Willson JKV (1992). Treatment of metastatic uveal melanoma: Review and recommendation. Surv Ophthalmol 36:429-438.
2. Albert DM, Ryan LM, and Borden EC (1996). Metastatic ocular and cutaneous melanoma: A comparison of patient characteristics and prognosis. Arch Ophthalmol 114:107-108.
3. Bedikian AY, Kantarjian H, Young SE, and Bodey GP (1981). Prognosis in metastatic choroidal melanoma. South Med J 74:574-577.
4. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, and Benjamin RS (1995). Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76:1665-1670.
5. Bianchi E, Cohen RL, Dai A, Thor AD, Shuman MA, and Smith HA (1995). Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer, Int J Cancer 60:597-603.
6. Callender GR (1931). Malignant melanotic tumors of the eye: A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 36:131-142.
7. Callender GR, Wilder HC, and Ash JE (1942). Five hundred malignant melanomas of the choroid and ciliary body followed five years or longer. Trans Am Acad Ophthalmol Otolaryngol 46:223-230.
8. Cattoretti G, Andreola S, Clemente C, D'Amato L, and Rilke F (1988). Vimentin and p53 expression on EGFr-positive, estrogen receptor-negative breast carcinomas. Br J Cancer 57:353-357.
9. Char DH (1978). Metastatic choroidal melanoma. Am J Ophthalmol 86:76-80.
10. Chu YW, Runyan RB, Oshima RG, and Hendrix MJ (1993). Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 90:4261-4265.
11. Chu YW, Seftor EA, Romer LH, and Hendrix MJ (1996). Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol 148:63-69.
12. Clemente CG, Mihm MG, Bufalino R, Zurrida S, Collini P, and Cascinelli N (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310.
13. Coupland SE, Sidiki S, Clark BJ, McClaren K, Kyle P, and Lee WR (1996). Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Arch Ophthalmol 114: 751-756.
14. Cress AE and Dalton WS (1996). Multiple drug resistance and intermediate filaments. Cancer Metastasis Rev 15:499-506.
15. Daniels KJ, Boldt HC, Martin JA, Gardner LM, Meyer M, and Folberg R (1996). Expression of Type VI collagen in uveal melanoma: Role in pattern formation and tumor progression. Lab Invest 75:55-66.
16. de la Cruz POJ, Specht CS, and McLean IW (1990). Lymphocytic infiltration in uveal malignant melanoma. Cancer 65: 112-115.
17. Diebold Y, Blanco G, Saornil MA, Fernandez N, and Lazaro MC (1997). Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma- and melanocytes-derived). Curr Eye Res 16:487-495.
18. Donoso LA, Shields JA, Augsburger JA, Orth DH, and Johnson P (1985). Metastatic uveal melanoma: Diffuse hepatic metastasis in a patient with concurrent normal serum enzyme levels and liver scan (letter). Arch Ophthalmol 103:758.
19. Einhorn LH, Burgess MA, and Gottlieb JA (1974). Metastatic patterns of choroidal melanoma. Cancer 34:1001-1004.
20. Folberg R (1993). Tumor progression in ocular melanomas. J Invest Dermatol 100:3263-3315.
21. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, and Gruman LM (1993). The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100:1389-1398.
22. Franke WW, Schmid E, and Moll R (1983). The intermediate fiilament cytoskeleton in tissues and cultured cells: Differentation specificity of expression of cell architectural elements. In: Harris CC and Autrup HN, editors. Human carcinogenesis. New York: Academic Press, 3-34.
23. Fuchs E and Wever K (1994). Intermediate filaments: Structure, dynamics, function, and disease. Annu Rev Biochem 63:345-382.
24. Fuchs U, Kivela T, Summanen P, Immonen I, and Tarkkanen A (1992). An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 141:169-181.
25. Hendrix MJ, Seftor EA, Chu YW, Seftor REB, Nagle RB, McDaniel KM, Leong SPL, Yohem KH, Liebovitz AM, Meyskens FL Jr, Conaway DH, Welch DR, Liotta La, and Stetler-Stevenson WG (1992). Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and invasive and metastatic potential. J Natl Cancer Inst 84:165-174.
26. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, and Seftor REB (1996). Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 1997 15:507-525.
27. Hendrix MJ, Seftor EA, Seftor RE, and Fidler IJ (1987). A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38:137-147.
28. Hendrix MJ, Seftor EA, Seftor RE, Gardner LM, Boldt HC, Meyer M, Pe'er J, Folberg R. (in press, 1998) Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol.
29. Hendrix MJ, Seftor EA, Seftor RE, and Trevor KT (1997). Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150:483-495.
30. Huszar M, Halkin H, Herczeg E, Bubis J, and Geiger B (1983). Use of antibodies to intermediate filaments in the dignosis of metastatic melanoma. Hum Pathol 14:1006-1008.
31. Kan-Mitchell J, Mitchell MS, Rao N, and Liggett PE (1989). Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 30:829-834.
32. Kan-Mitchell J, Rao N, Albert DM, Van Eldik LJ, and Taylor CR (1990). S100 immunophenotypes of uveal melanomas. Invest Ophthalmol Vis Sci 31:1492-1496.
33. Klymkowsky MW (1996). Intermediate filaments as dynamic structures. Cancer Metastasis Rev 15:417-428.
34. Klymkowsky MW, Bachant JB, and Domingo A (1989). Functions of intermediate filaments. Cell Motil Cytoskeleton 19: 67-79.
35. Kohn EC and Liotta LA (1995). Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55:1856-1862.
36. Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
37. Lorigan JG, Wallace S, and Mavligit GM (1991). The prevalence and location of metastases from ocular melanoma: Imaging study in 110 patients. AJR Am J Roentgenol 157: 1279-1281.
38. Marshall GE, Konstas AGP, Reid GG, Edwards JG, and Lee WR (1994). Collagens in the aged human macula. Graefes Arch Clin Exp Ophthalmol 232:133-140.
39. McLean IW (1995). Small choroidal melanocytic lesions. Ophthalmology 102:1361-1361.
40. McLean IW, Berd D, Mastrangelo MJ, Shields JA, Davidorf FH, Grever M, Makley TA, and Gamel JW (1990). A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. Am J Ophthalmol 110:522-526.
41. McLean IW, Foster WD, Zimmerman LE, and Gamel JW (1983). Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 96:502-509.
42. Mehaffey MG, Rummelt V, Naumann GOH, and Folberg R (1997). Microcirculation architecture of metastases from primary uveal melanoma (abstract). Invest Ophthalmol Vis Sci 38:S807.
43. Miettinen M and Fransella K (1989). Immunohistochemical spectrum of malignant melanoma: The common presence of keratins. Lab Invest 61:623-628.
44. Mooy CM and De Jong PTVM (1996). Prognostic parameters in uveal melanoma: A review. Surv Ophthalmol 41:215-228.
45. Osborn M and Weber K (1982). Cell-type-specific markers in differentiation and pathology. Cell 31:303-306.
46. Osborn M and Weber K (1983). Tumor diagnosis by intermediate filament typing: A new tool for surgical pathology. Lab Invest 48:372-394.
47. Panigel K, Hedelin G, Speeg-Schatz C, Sahel J, and Brini A (1992). Prognostic factors of choroidal melanoma: An anatomo-clinical retrospective and statistical study of 76 enucleated cases. J Fr Ophtalmol 15:410-414.
48. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, and Halpern AC (1996). A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med 125:369-375.
49. Seddon JM, Polivogianis L, Hsieh CC, Albert DM, Gamel JW, and Gragoudas ES (1987). Death from uveal melanoma: Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol 105:801-806.
50. Shammas HF and Blodi FC (1977). Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 95:63-69.
51. Skalli O and Goldman RD (1991). Recent insights into the assembly, dynamics, and function of intermediate filament networks. Cell Motil Cytoskeleton 19:67-79.
52. Sommers CL, Byers SW, Thompson EW, Torri JA, and Gelmann EP (1994). Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31:325-335.
53. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thoompson EW, Byers SW, and Gelmann EP (1992). Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 52:5190-5197.
54. Steinert PM and Leim RK (1990). Intermediate filament dynamics. Cell 60:521-523.
55. Thompson EW, Soonmyoung P, Brunner N, Sommers CL, Sugmaler G, Clarke R, Shima TB, Torri J, Donahue S, Lippmann ME, Martin GR, and Dickson RB (1992). Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150:534-544.
56. Wilder HC and Callender GR (1939). Malignant melanoma of the choroid: Further studies on prognosis by histologic type and fiber content. Am J Ophthalmol 22:851-855.
57. Zakka KA, Foos RY, Omphroy CA, and Straatsma BR (1980). Malignant melanoma: Analysis of an autopsy population. Ophthalmology 87:549-556.
58. Zarbo RJ, Gown AM, and Nagle RB (1990). Anomalous cytokeratin expression in malignant melanoma: One- and two-dimensional Western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 3:494-501.
59. Zimmerman LE and McLean IW (1984). Do growth and onset of symptoms of uveal melanomas indicate subclinical metastasis? Ophthalmology 92:685-691.